Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Elanco Animal Health Incorporated ELAN

Healthcare  —  Drug Manufacturers Specialty & Generic
22.31 (0.04) (0.18%) as of 25 Sep
Market cap
$11.2B
P/E
0.0×
Revenue Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Elanco Animal Health Incorporated (ELAN) Business Profile

Updated before January 2025

Company Overview

Elanco Animal Health Incorporated (ELAN) is a global leader in animal health, dedicated to innovating and delivering products and services that enhance the health and well-being of animals. Founded in 1954 as a division of Eli Lilly and Company, Elanco became an independent publicly traded company in 2018. Headquartered in Greenfield, Indiana, USA, Elanco operates in over 90 countries worldwide. The company is led by its President and CEO, Jeffrey Simmons, who has been instrumental in driving Elanco’s growth and innovation. Elanco’s mission is to provide solutions that empower veterinarians, farmers, and pet owners to care for animals responsibly and sustainably.

Core Business Segments

Elanco’s business is divided into two primary segments: Farm Animal and Companion Animal. Each segment focuses on specific products and services tailored to meet the needs of its target audience.

Farm Animal

Elanco’s Farm Animal segment provides solutions for livestock producers, focusing on improving animal health, productivity, and sustainability. Key product categories include:

  • Cattle: Products for beef and dairy cattle, including vaccines, antibiotics, and nutritional supplements.
  • Swine: Solutions for swine health, such as feed additives, vaccines, and treatments for parasitic infections.
  • Poultry: Products aimed at enhancing poultry health and productivity, including vaccines and feed additives.
  • Aquaculture: Solutions for fish farming, including treatments for sea lice and other aquatic diseases.

Companion Animal

The Companion Animal segment focuses on products for pets, primarily dogs and cats. Key offerings include:

  • Parasiticides: Treatments for fleas, ticks, and other parasites, such as Credelio® and Seresto®.
  • Vaccines: Preventative care solutions for common pet diseases.
  • Therapeutics: Products addressing chronic conditions like arthritis and pain management, including Galliprant®.
  • Nutritional Health: Supplements and specialized diets to support pet health.

Business Model

Elanco’s business model revolves around innovation, customer-centric solutions, and a diversified product portfolio. The company invests heavily in research and development (R&D) to create new products and improve existing ones. Elanco generates revenue through the sale of its products to veterinarians, farmers, and pet owners via a global network of distributors and retailers. Additionally, the company offers value-added services, such as educational programs and consulting, to strengthen customer relationships and drive loyalty.

Strategic Direction

Elanco is committed to driving growth through innovation, sustainability, and strategic acquisitions. Key elements of its strategic direction include:

  • Innovation: Continued investment in R&D to develop new products and technologies that address emerging animal health challenges.
  • Sustainability: A focus on reducing the environmental impact of its operations and products, including initiatives to promote sustainable farming practices.
  • Portfolio Expansion: Exploring new product categories, such as digital health solutions and diagnostics, to diversify its offerings.
  • Global Expansion: Strengthening its presence in emerging markets to capitalize on growing demand for animal health products.

Competitive Landscape

Elanco operates in a highly competitive industry, facing competition from both established players and new entrants. Key competitors include:

  • Zoetis Inc.: A leading animal health company with a broad portfolio of products for livestock and pets.
  • Boehringer Ingelheim Animal Health: Known for its innovative solutions in animal health.
  • Merck Animal Health: A division of Merck & Co., offering a wide range of vaccines and pharmaceuticals.
  • Bayer Animal Health: Recently acquired by Elanco, strengthening its position in the market.
  • Ceva Santé Animale: A global player specializing in vaccines and pharmaceuticals for animals.

Risk Factors

Elanco faces several risks that could impact its business, including:

  • Market Dependence: Reliance on a few key products for a significant portion of revenue.
  • Regulatory Challenges: Compliance with stringent regulations in different markets.
  • Supply Chain Disruptions: Potential disruptions due to geopolitical events, natural disasters, or pandemics.
  • Competition: Intense competition from established players and new entrants.
  • Economic Factors: Fluctuations in commodity prices and currency exchange rates.

Recent Developments

Elanco has made significant strides in recent years, including:

  • Acquisition of Bayer Animal Health: Completed in 2020, this acquisition expanded Elanco’s product portfolio and global reach.
  • Launch of New Products: Introduction of innovative products like Credelio® Plus, a combination parasiticide for dogs.
  • Sustainability Initiatives: Commitment to achieving carbon neutrality by 2050 and promoting sustainable farming practices.
  • Digital Health Solutions: Development of digital tools to support veterinarians and pet owners in managing animal health.

Investment Considerations

Investors considering Elanco should weigh the following strengths and risks:

Strengths

  • Strong Market Position: A leading player in the animal health industry with a diversified product portfolio.
  • Innovation-Driven: Significant investment in R&D to drive growth and maintain a competitive edge.
  • Global Presence: Operations in over 90 countries, providing access to diverse markets.
  • Strategic Acquisitions: Successful integration of Bayer Animal Health, enhancing its capabilities.

Risks

  • Market Dependence: Reliance on a few key products for revenue.
  • Regulatory Risks: Compliance challenges in different markets.
  • Economic Uncertainty: Exposure to fluctuations in commodity prices and currency exchange rates.

Conclusion

Elanco Animal Health Incorporated is a global leader in animal health, with a strong commitment to innovation, sustainability, and customer-centric solutions. While the company faces challenges such as market dependence and regulatory risks, its diversified product portfolio, strategic acquisitions, and focus on emerging markets position it well for future growth. As the demand for animal health products continues to rise, Elanco is poised to capitalize on new opportunities and maintain its leadership in the industry.